Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;11(7):1247-1267.
doi: 10.21037/tlcr-22-527.

Expert consensus on perioperative treatment for non-small cell lung cancer

Affiliations
Review

Expert consensus on perioperative treatment for non-small cell lung cancer

Jianchun Duan et al. Transl Lung Cancer Res. 2022 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-527/coif). CZ serves as an Editor-in-Chief of Translational Lung Cancer Research from August 2014 to July 2022. SHL serves as an unpaid editorial board member of Translational Lung Cancer Research from September 2019 to September 2023. GM serves as an unpaid editorial board member of Translational Lung Cancer Research from February 2016 to July 2023. CG serves as an unpaid editorial board member of Translational Lung Cancer Research from September 2019 to September 2023, and received honoraria as speaker bureau or advisory board member or consulting fees form Menarini, Roche, Eli Lilly, Boehringer, Amgen, Pfizer, Novartis, MSD, BMS, Astra Zeneca, Takeda, Novartis, GSK, Karyopharm. Qing Z received lecture and presentations fees from AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche, and Sanofi. AB received consulting fees as an Advisory Board with Astra Zeneca, BD, Ethicon, Medtronic, Roche, and is the president of European Society of Thoracic Surgeons. TJ received consulting fees from Roche, Merck, MSD, Puma, AstraZeneca, BMS, Amgen, Gilead, Specialised Therapeutics. DHO reports research funding (to institution) from Genentech, BMS, Merck, Pfizer, Palobiofarma, and Onc. AI. MR received honoraria for lectures and expert meetings from Astrazeneca, and also received honoraria for lectures and expert meetings as well as travel expenses from Abex. KS received a research grant from Boehringer-Ingelheim, through Kindai University Faculty of Medicine, has received consulting fees from AstraZeneca, and has received honoraria from Chugai, Taiho, and AstraZeneca. FT received speaker bureau from AstraZeneca. The other authors have no conflicts of interest to declare.

Comment in

  • The path forward in early-stage lung cancer.
    Cuppens K, Baas P. Cuppens K, et al. Transl Lung Cancer Res. 2023 Jan 31;12(1):11-13. doi: 10.21037/tlcr-22-546. Epub 2022 Dec 30. Transl Lung Cancer Res. 2023. PMID: 36762062 Free PMC article. No abstract available.

References

    1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7-33. 10.3322/caac.21708 - DOI - PubMed
    1. Melzer AC, Triplette M. Screening high risk populations for lung cancer. BMJ 2022;376:o666. 10.1136/bmj.o666 - DOI - PubMed
    1. Kehl KL, Zahrieh D, Yang P, et al. Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). JAMA Oncol 2022;8:717-28. 10.1001/jamaoncol.2022.0039 - DOI - PMC - PubMed
    1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9. 10.1200/JCO.2007.13.9030 - DOI - PubMed
    1. NSCLC Meta-analysis Collaborative Group . Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 2014;383:1561-71. 10.1016/S0140-6736(13)62159-5 - DOI - PMC - PubMed